MLL Münchner Leukämielabor GmbH

Industry / private company

München, Germany

Publications in cooperation with FAU scientists

Saussele, S., Hehlmann, R., Fabarius, A., Jeromin, S., Proetel, U., Rinaldetti, S.,... Lauseker, M. (2018). Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia, 32(5), 1222-1228.
Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H.J.,... Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31(11), 2398-2406.
Krappe, S., Benz, M., Wittenberg, T., Haferlach, T., & Münzenmayer, C. (2015). Automated classification of bone marrow cells in microscopic images for diagnosis of leukemia: A comparison of two classification schemes with respect to the segmentation quality. In Proc. SPIE 9414,. Orlando.
Krappe, S., Münzenmayer, C., Evert, A., Can, K., Cetin, E., Haferlach, T.,... Held, C. (2015). Dynamic programming for the segmentation of bone marrow cells. In Bildverarbeitung für die Medizin 2015 (pp. 359-364). Lübeck: Heidelberg: Springer.
Fabarius, A., Kalmanti, L., Dietz, C.T., Lauseker, M., Rinaldetti, S., Haferlach, C.,... Hehlmann, R. (2015). Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Annals of Hematology, 94(12), 2015-24.
Hehlmann, R., Müller, M.C., Lauseker, M., Hanfstein, B., Fabarius, A., Schreiber, A.,... Hochhaus, A. (2014). Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. Journal of Clinical Oncology, 32(5), 415-23.
Hanfstein, B., Lauseker, M., Hehlmann, R., Saussele, S., Erben, P., Dietz, C.,... Mueller, M.C. (2014). Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica, 99(9), 1441-7.
Hanfstein, B., Shlyakhto, V., Lauseker, M., Hehlmann, R., Saussele, S., Dietz, C.,... Mueller, M.C. (2014). Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia, 28(10), 1988-92.
Kalmanti, L., Saussele, S., Lauseker, M., Proetel, U., Mueller, M.C., Hanfstein, B.,... Hehlmann, R. (2014). Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Annals of Hematology, 93(1), 71-80.

Last updated on 2016-07-06 at 12:15